Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-01-18
2011-01-18
Shameem, Golam M. M. (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C548S962000
Reexamination Certificate
active
07872145
ABSTRACT:
The present invention is directed to aziridinyl epothilone compounds as further described herein, and/or pharmaceutically-acceptable salts and/or solvates thereof having the following Formula:wherein K is —O—, —S—, or —NR7—; A is —(CR8R9)—(CH2)m—Z—wherein Z is —(CHR10)—, —C(═O)—, —C(═O)—C(═O)—, —OC(═O)—, —N(R11)C(═O)—, —SO2—, or —N(R11)SO2—; B1is hydroxyl or cyano and R1is hydrogen or B1and R1are taken together to form a double bond; R2, R3, and R5are, independently, hydrogen, alkyl, substituted alkyl, aryl or substituted aryl; or R2and R3may be taken together with the carbon to which they are attached to form an optionally substituted cycloalkyl; R4is hydrogen, alkyl, alkenyl, substituted alkyl, substituted alkenyl, aryl, or substituted aryl; R6is hydrogen, alkyl or substituted alkyl; R7, R8, R9, R10, R11and R12are independently hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, or substituted heteroaryl; and R13is aryl, substituted aryl, heteroaryl or substituted heteroaryl.
REFERENCES:
patent: 5416016 (1995-05-01), Low et al.
patent: 6291673 (2001-09-01), Fuchs et al.
patent: 6291684 (2001-09-01), Borzilleri et al.
patent: 6399638 (2002-06-01), Vite et al.
patent: 6800653 (2004-10-01), Regueiro-Ren et al.
patent: 2005/0002942 (2005-01-01), Vlahov et al.
patent: 00/66091 (2000-11-01), None
patent: 02/098868 (2002-12-01), None
patent: 2004/012735 (2004-02-01), None
patent: 2004/054622 (2004-07-01), None
patent: 2005/074901 (2005-08-01), None
patent: 2006/042146 (2006-04-01), None
Regueiro-Ren et al. Organic Letters, 2001, vol. 3, No. 17, pp. 2693-2696.
Melby, et al., “Entry of Protein Toxins in Polarized Epithelial Cells”, Cancer Research., vol. 53 (1993) 1755-60.
Olsnes, et al., “Immunotoxins entry cells and mechanisms of action”, Immunology Today, vol. 10, No. 9 (1989) 291-95.
Regueiro-Ren, et al., “Synthesis and Biological Activity of Novel Epothilone Aziridines”, Organic Letters, vol. 3, No. 17 (2001) 2693-96.
Kamen, et al., “A review of folate receptor alpha cycling and 5-methyltetrahydrofolate accumulation with an emphasis on cell models in vitro”, Advanced Drug Delivery Reviews, vol. 56 (2004) 1085-97.
Jackman, et al., “Antifolates targeted specifically to the folate receptor”, Advanced Drug Delivery Reviews, vol. 56 (2004) 1111-25.
Elnakat, et al., “Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy”, Advanced Drug Delivery Reviews, vol. 56 (2004) 1067-84.
Sabharanjak, et al., “Folate receptor endocytosis and trafficking”, Advanced Drug Delivery Reviews, vol. 56 (2004) 1099-1109.
Paulos, et al., “Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis”, Advanced Drug Delivery Reviews, vol. 56 (2004) 1205-17.
Antony, “Folate receptors: reflections on a personal odysssey and a perspective on unfolding truth”, Advanced Drug Delivery Reviews, vol. 56 (2004) 1059-66.
“Folate Receptor-Targeted Drugs for Cancer and Inflammatory Diseases”, Advanced Drug Delivery Reviews, vol. 56 (2004) vol. 56, No. 8 (2004) 1055-58.
Lu, et al., “Folate receptor-targeted immunotherapy of cancer: mechanism and therapeutic potential”, Advanced Drug Delivery Reviews, vol. 56 (2004) 1161-76.
Roy, et al., “Folate-mediated targeting of T cells to tumors”, Advanced Drug Delivery Reviews, vol. 56 (2004) 1219-31.
Ke, et al., “Folate-receptor-targeted radionuclide imaging agents”, Advanced Drug Delivery Reviews, vol. 56 (2004) 1143-60.
Leamon, et al., “Folate-targeted chemotherapy”, Advanced Drug Delivery Reviews, vol. 56 (2004) 1127-41.
Gabizon, et al., “Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates”, Advanced Drug Delivery Reviews, vol. 56 (2004) 1177-92.
Zhao, et al., “Tumor-selective targeted delivery of genes and antisense oligodeoxyribonucleotides via the folate receptor”, Advanced Drug Delivery Reviews, vol. 56 (2004) 1193-1204.
Leamon Christopher P.
Lee Francis Y.
Vite Gregory D.
Vlahov Iontcho R.
Bristol-Mysers Squibb Company
Chao Yuan
Duncan Laurelee
Otton Alicia L
Shameem Golam M. M.
LandOfFree
Aziridinyl-epothilone compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aziridinyl-epothilone compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aziridinyl-epothilone compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2698118